Improving Anticoagulation Measurement
Novel Warfarin Composite Measure

Zayd Razouki, MD, MSc; James F. Burgess, Jr, PhD; Al Ozonoff, PhD; Shibei Zhao, MPH; Dan Berlowitz, MD, MPH; Adam J. Rose, MD, MSc

Background—Percent time in therapeutic range (TTR) and international normalized ratio (INR) variability both measure warfarin control and are associated with outcomes independently. Here, we examine the advantages of a warfarin composite measure (WCM), which summarizes the 2 when measuring patient outcomes. We also examine how the measure chosen would affect anticoagulation clinic performance rankings.

Methods and Results—We constructed WCM using an equally weighted method, adding standardized TTR to standardized log-transformed INR variability using 103,897 warfarin-experienced patients from 100 anticoagulation clinics. We examined the association of WCM with ischemic stroke, major bleeding, and fatal bleeding, using a subset of patients with atrial fibrillation (n=40,404). We divided patients into quintiles based on their level of control for TTR, log INR variability, and WCM. We calculated the hazard ratios for ischemic stroke, major bleeding, and fatal bleeding stratified by these quintiles. WCM hazard ratios for stroke and fatal bleeding showed the largest difference between excellent control and poorest control quintile compared with TTR and log INR variability, but not for major bleeding. In addition, we compared site rankings obtained using each of our 3 performance measures. Kappa scores for identifying outlier and nonoutlier clinics between WCM and its components were moderate (κ=0.56 for TTR and κ=0.62 for log INR variability) but was weak between TTR and log INR variability (κ=0.13).

Conclusions—WCM produces the largest range of risk for warfarin complications, widening the floor ceiling effects that limit the use of TTR and INR variability as separate measures. Anticoagulation clinics ranking changed considerably according to the anticoagulation measure that was selected. (Circ Cardiovasc Qual Outcomes. 2015;8:600-607. DOI: 10.1161/CIRCOUTCOMES.115.001789.)

Key Words: atrial fibrillation ■ blood coagulation ■ international normalized ratio ■ quality of care ■ stroke ■ warfarin

Despite the introduction of other anticoagulants in recent years, warfarin remains by far the most commonly used anticoagulant and will for years to come. It is effective in preventing ischemic strokes in atrial fibrillation and in treating patients with thromboembolic diseases. However, its efficacy depends on its level of control. Previous studies have shown that when control is poor, patients experience more warfarin-associated complications, including strokes, bleeding, and death. Therefore, improving warfarin anticoagulation is central for reducing the complications associated with its use. Improving the quality of anticoagulation management is contingent on defining what constitutes good or poor control and using valid ways to measure it.

An intermediate outcome measure can be defined as a physiological parameter which does not itself constitute a clinical outcome, but has been robustly linked to one. An example would be blood pressure control, which is associated with cardiovascular outcomes, including stroke and myocardial infarction. In anticoagulation care, there are 2 main intermediate outcome measures that have been used to assess the level of anticoagulation control: (1) percent time in therapeutic range (TTR) and (2) international normalized ratio (INR) variability. Each one measures a different aspect of anticoagulation control. TTR is a quantitative measure that reflects the percentage of the appropriate intensity, and not necessarily the stability, of the anticoagulation regimen and has been shown to successfully be associated with clinical outcomes. Low level of TTR has been associated with higher rates of ischemic stroke, major bleeding, and death. In addition, TTR has been validated to serve as a performance

© 2015 American Heart Association, Inc.

Circ Cardiovasc Qual Outcomes is available at http://circoutcomes.ahajournals.org

DOI: 10.1161/CIRCOUTCOMES.115.001789
WHAT IS KNOWN

- Percent time in therapeutic range (TTR, a measure of anticoagulation intensity) and international normalized ratio (INR) variability (a measure of anticoagulation stability) are 2 different independent measures that are associated with adverse events with warfarin therapy.
- TTR and INR variability together provide more information about risk of warfarin adverse events than each individually.

WHAT THE STUDY ADDS

- Warfarin composite measure is a novel and valid summary score that combines TTR and INR variability, thus accounting for both the intensity and stability of warfarin therapy.
- Warfarin composite measure produces the largest range of risk for warfarin complications, reducing the measurement constrains that limit the use of TTR and INR variability as separate measures.
- Warfarin composite measure, as a performance measure, reconciles the discordance in ranking anticoagulation clinics that occurs when using TTR or INR variability separately.

standard of care, TTR. A comprehensive performance measure would also facilitate quality improvement efforts that can succeed in improving both dimensions of good control.

Methods

Data Collection

The database for this study has been described elsewhere. In brief, the Veterans Affairs Study to Improve Anticoagulation (VARIA) included all patients considered to be receiving oral anticoagulation therapy from the VA between October 1, 2006 and September 30, 2008. For this study, we only included those patients who had previously received warfarin for at least 6 months within the VHA system (ie, experienced warfarin users). Patients who completed their 6-month initiation phase before October 1, 2006 were included from the beginning of the period; other patients entered the database after completing 6 months of therapy. Patients who are prescribed warfarin from the VA are fully managed in special ACCs, whereas patients who are prescribed warfarin outside the VA are not included in this data set.

The study was approved by the Institutional Review Board of the Bedford VA Medical Center.

Patients

Our full sample included all patients (n=103,897) who already received warfarin for at least 6 months from the VA during the FY07 to FY08 (ie, at least 30 days’ worth dispensed by the pharmacy). We included INR tests within the VA when patients were on warfarin, that is, when a patient was either (1) in possession of warfarin or (2) having INR tests every 42 days. A similar approach was used to define time on warfarin. We defined the period of warfarin possession as the duration of the most recent VA prescription for warfarin, plus 30 days. Because patients may be instructed to take half doses of warfarin, we recognize that going >30 days beyond the end of a prescription does not necessarily indicate that warfarin therapy has stopped. We therefore also allowed a consistent pattern of INR measurements (ie, every 42 days or less) to indicate that a patient was still being managed. Patients with chronic liver disease were only included if they received warfarin; frequent INR tests for such patients might have been performed to monitor liver function.

INR values during hospitalization and 14 days after discharge were excluded in this study and were not used to calculate the 3 anticoagulation measures, reasoning that warfarin management might be held for clinically important scenarios, including procedures and bleeding events. We excluded patients whose primary indication to receive warfarin was valvular heart disease, because their target INR range might be 2.5 to 3.5 rather than the conventional target of 2 to 3, which would change the calculation of TTR. We also excluded patients who only recorded INR values 1.3 and lower, reasoning that most such patients received INR tests for reasons unrelated to warfarin management (eg, frequent emergency department visits).

For our first aim, comparing the risk of warfarin-associated complications for each anticoagulation measure, we limited our sample to patients who were receiving anticoagulation for atrial fibrillation, as opposed to other indications, such as venous thromboembolism. This was done to create a sample of patients with relatively uniform risk for the outcomes of interest. We also limited this portion of our study to patients >65 years, who were enrolled in fee-for-service Medicare. Patients with Medicare Advantage plans were excluded because that program does not produce itemized claims data, which would lead to undercounting of events that occurred outside the VHA. We used a merged VHA-Medicare database to maximize the possibility of capturing all relevant events and complications related to warfarin therapy. After these exclusions, we were left with (n=40,404) patients for the study of clinical outcomes.

For the second aim of this study (ie, examining the impact of the selected measure on site performance profiling), we used our full sample (n=103,897), as described above.

Laboratory Values

To calculate measures of INR control, we included INR values obtained within the VA system when patients were on warfarin, that is,
when a patient was either (1) in possession of warfarin or (2) having INR tests at least every 42 days. We defined the period of warfarin possession as the duration of the most recent VA prescription for warfarin, plus 30 days. Because patients may be instructed to take half doses of warfarin, we recognize that going >30 days beyond the end of prescription does not necessarily indicate that warfarin therapy has stopped. We therefore allowed a consistent pattern of INR measurements (ie, every 42 days or less) to indicate that a patient was still being managed.

We excluded INR tests measured while the patient was hospitalized within the VA system. Patients who are hospitalized may receive temporary parental anticoagulation (eg, with heparin) or no anticoagulation, so out-of-range INR values while hospitalized may be intentional and do not necessarily reflect poor quality care.

Calculating Percent Time in TTR
We calculated TTR using the method by Rosendaal, which uses linear interpolation to assign an INR value to each day between successive observed INR values. Gaps of 56 days or more between INR values are not interpolated. After interpolation, we calculated the percentage of time during which the interpolated INR values lie between 2.0 and 3.0 (from 0% to 100%).

Calculating INR Variability
INR variability was calculated using the method of Fihn, which reflects the degree to which each patient’s INR varies around his or her previous INR. This formula does not take into account the intensity of warfarin therapy; a patient is most stable if his or her INRs are around the same level even if the INR is constantly above or below the limits of the target range. We log-transformed INR variability to reduce the leverage and undue influence of extreme observations on our estimates. More negative INR variability values are actually consistent with better control. For example, a patient with log INR variability of −5.0 has a much more stable anticoagulation regimen compared with another patient with a log INR variability of −0.75.

Constructing the Composite Measure (WCM)
We constructed WCM using an equally weighted approach, where each individual measure is simply added to the other. An equally weighted approach is the default approach when constructing a composite measure and when there is no clear rationale that a measure should be weighted different from the other. Furthermore, we justify weighting TTR and log INR variability equally based on the absolute values of the coefficients of variation that were found to be comparable in magnitude (35.8 for TTR and −42.5 for log INR Variability). In addition, both TTR and log INR variability have similar c-statistics when predicting our study outcomes, and when there is no clear rationale that a measure should be weighted different from the other. Furthermore, we justify weighting TTR and log INR variability equally based on the absolute values of the coefficients of variation that were found to be comparable in magnitude (35.8 for TTR and −42.5 for log INR Variability). In addition, both TTR and log INR variability have similar c-statistics when predicting our study outcomes.

Primary Outcomes
To examine the first study aim, we compared 3 main outcomes: ischemic stroke, major bleeding, and fatal bleeding, which is a subset of major bleeding where death occurred within 30 days. We compared these outcomes across our 3 anticoagulation measures: TTR, log INR variability, and WCM.

The outcome of death was assessed using the VA Vital Status Mini-File, which is known to be an accurate source for date of death.22 We identified major bleeding using a method we have previously described.21 Briefly, we began with all International Classification of Diseases-Ninth Revision codes that might describe a hemorrhagic event and then retained the events that fulfilled 1 of 4 criteria: fatal hemorrhage, bleeding into a critical anatomic site, bleeding associated with transfusion, or bleeding which was identified as the main reason for a hospital stay. This is an adaptation of the definition of major bleeding of the International Society of Thrombosis and Haemostasis to a large, automated data set.24 Ischemic strokes were also defined using International Classification of Diseases-Ninth Revision codes. We used a restrictive set of codes to define our stroke outcome, emphasizing specificity over sensitivity. Namely, we used 433.x1 and 434.x1, Occlusion of…artery…with cerebral infarction. We only used inpatient codes for this outcome, as per our earlier work,25 but did allow codes in either the primary or secondary position to define a stroke.

Covariates
We adjusted for various clinical variables that are known to be associated with our outcomes. For ischemic strokes, we adjusted for all of the variables included in the CHADS2 score (congestive heart failure, hypertension, age, diabetes mellitus, and previous stroke/transient ischemic attack).26 For major and fatal bleeding, we adjusted for many of the variables contained within the HAS-BLED bleeding risk score,27 including age, hypertension, chronic kidney disease, liver disease, prior stroke, alcohol abuse, and drug abuse. We did not adjust for other components of HAS-BLED, such as history of major bleeding and antiplatelet therapy, because we could not identify those elements with confidence in our data set.

Anticoagulation Clinics
Patients receiving warfarin are managed by specialized ACCs in the VA healthcare system where each clinic is attached to a medical care site. There are 128 ACC of care in the VHA system. We excluded 28 of these clinics from our study because our data-checking procedures revealed possible problems with data completeness at those clinics that have been fully described in a published article.28 We also excluded several months of data from an additional 14 clinics for the same reason.

Risk Adjustment Model
We used our full sample (n=103,897) to examine how using different anticoagulation measure as performance measures could affect ACC ranking. A risk adjustment model that our group previously used to adjust TTR was also used to risk-adjust log INR variability.29 The derivation and validation of this model, including the definitions of our clinical variables, using International Classification of Diseases-Ninth Revision codes, is fully described in a previously published article.20 Table I in the Data Supplement shows covariates included in our model, with applicable β-coefficients for TTR and log INR variability.

Variables contained within the model include sociodemographic factors (age, sex, race, area-level poverty, and distance from care), factors characterizing warfarin therapy (indication for therapy, how long ago therapy began), and factors characterizing illness burden (physical and mental comorbid health conditions, number of medications, and number of hospitalizations). We computed new coefficients for these variables, first to examine the association with log INR variability, then to examine their associations with WCM.

Statistical Analyses
To compare the association of WCM and its components (TTR and log INR variability) with clinical outcomes, we divided each measure into

WCM = [Standardized TTR + (Standardized log INR variability * −1]
quintiles and assigned patients into these quintiles based on their degree of control with each measure. Patients were often assigned to different quintiles using different measures. First, we calculated the crude percentage of our outcomes (ischemic stroke, major bleeding, and fatal bleeding) within each quintile. Then, we calculated hazard ratios (HRs) for each of our outcomes (ischemic stroke, major bleeding, and fatal bleeding) using Cox regression analyses. The quintile excellent control was used as a reference category. We visually compared the HRs for outcomes across quintiles. We were not able to perform statistical comparison testing to query whether differences in HRs were statistically significant, because individual patients were not distinctly separated across the 3 studied measures, and there is no statistical test that can be used to compare across the 3 independent variables. Therefore, estimates are to be compared visually.

To examine whether WCM better discriminates patient outcomes compared with TTR and log INR variability, we calculated the statistic for each measure examining major bleeding, fatal bleeding, and stroke. We performed a full sample bootstrap with 300 iterations of resampling. For each iteration, we calculated the statistic and calculated the 2.5% and 97.5% quintiles of the resulting distribution as the lower and upper limits of the empirical confidence interval.

To illustrate the distribution and frequency of our sample across various levels of anticoagulation control according to the 3 anticoagulation measures, we created 3 5×5 tables, dividing each measure into quintiles based on the level of control.

To profile ACCs according to the 3 anticoagulation measures, we calculated descriptive statistics for TTR, log INR variability, and WCM. We then applied a linear regression model to risk-adjust log INR variability, calculating the expected (E) value for each clinic, and then we calculated observed minus expected value for each clinic. Adjusted TTR was calculated in a previous published study using a similar risk-adjustment model. The effect sizes that are associated with both measures were used to calculate the adjusted values for WCM.

Clinics were marked as outliers in their performance, if the absolute difference between an observed value and an expected value exceeded 1 SD, with a SD measured by the entire sample of patients. Using SD-based yardsticks to define important effect sizes is common when no consensus exists about what would be an important difference: a full SD is generally considered to be a large difference. We also examined the correlation among the ranking order of ACCs (1) before and after adjustment and (2) among the 3 anticoagulation measures. Finally, we calculated a chance-corrected weighted $k$ score to assess the level of agreement among our measures in defining high and low performance outlier clinics.

### Results

#### Comparing the Association and the Discriminative Ability for Each Anticoagulation Measure (TTR, INR Variability, and WCM) With Warfarin-Associated Complications

For this analysis, we included a subset of patients (n=40,404) above the age of 65 years with atrial fibrillation. Our sample was (98%) male with a mean age of 76 years. Patients were observed for ≤2 years, with an average observation time of 14 months. The mean values for TTR and log INR variability are reported for each quintile of anticoagulation control for this cohort in Table 1.

Time interpolated to measure TTR was, 44610.22 person-years, representing 80% of total time between INR intervals during our study period. The remaining time was excluded because time intervals longer than 56 days could not be interpolated according to the methods by Rosendaal. Such values were excluded from all calculations, not just those for TTR.

Overall, 3.1% of patients experienced an ischemic stroke event, 6.4% experienced a major bleeding, and 0.9% experienced fatal bleeding, a subset of major bleeding. Tables II to IV in the Data Supplement show the frequency of major bleeding, fatal bleeding, and ischemic stroke within each quintile for each anticoagulation measure.

Compared with log INR variability, WCM HRs for major bleeding showed the largest difference in outcomes between excellent control and other levels of anticoagulation control. Specifically, compared with excellent control, the HR for major bleeding was greater at levels of very poor control (HR: WCM=1.95 versus log INR variability=1.58) and poor control (HR: WCM=1.57 versus log INR variability=1.25). Compared with TTR, WCM had a similar HR between excellent control and other levels of control. Specifically, compared with excellent control, the HR for major bleeding was similar at levels of very poor control (HR: WCM=1.95 versus TTR=1.99). One exception was a slightly higher HR for major bleeding at the level of poor control (HR: WCM=1.57 versus TTR=1.35). Table 2 shows the HRs for major bleeding according to quintiles of anticoagulation.

Compared with TTR and log INR variability, WCM HRs for fatal bleeding showed the largest difference in outcomes between excellent control and other levels of control. Specifically, compared with excellent control, the HR for fatal bleeding was greater with very poor control (HR: WCM=3.04 versus TTR=2.18 versus log INR variability=2.43) or poor control (HR: WCM=1.69 versus TTR=1.46 versus log INR variability=1.29). Table 3 shows the HRs for fatal bleeding according to quintiles of anticoagulation control.

Similarly, compared with TTR and log INR variability, WCM HRs for ischemic stroke showed the largest difference in outcomes between excellent control and other levels of control. Specifically, compared with excellent control, the HR for

<table>
<thead>
<tr>
<th>Variables</th>
<th>n</th>
<th>Mean Age</th>
<th>Mean and (Range) TTR</th>
<th>Mean and (Range) Log INR Variability</th>
<th>Mean and (Range) WCM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall mean (SD)</td>
<td>40,404</td>
<td>76.78</td>
<td>63.56 (21.2)</td>
<td>−3.41 (1.35)</td>
<td>0 (1.0)</td>
</tr>
<tr>
<td>Quintile 1: poorest</td>
<td>8,080</td>
<td>77.02</td>
<td>37.61 (0 to 47.11)</td>
<td>−1.78 (−11.51 to 4.48)</td>
<td>−2.16 (−7.67 to 1.13)</td>
</tr>
<tr>
<td>Quintile 2: poor control</td>
<td>8,081</td>
<td>76.81</td>
<td>54.14 (47.12 to 60.89)</td>
<td>−2.93 (−4.48 to 3.82)</td>
<td>−0.6 (−1.13 to 0.13)</td>
</tr>
<tr>
<td>Quintile 3: fair control</td>
<td>8,081</td>
<td>76.68</td>
<td>64.58 (60.89 to 71.15)</td>
<td>−3.48 (−3.82 to 3.21)</td>
<td>0.28 (−0.13 to 0.67)</td>
</tr>
<tr>
<td>Quintile 4: good control</td>
<td>8,081</td>
<td>76.71</td>
<td>74.24 (71.15 to 81.76)</td>
<td>−3.99 (−3.21 to 2.40)</td>
<td>1.07 (0.67 to 1.52)</td>
</tr>
<tr>
<td>Quintile 5: excellent control</td>
<td>8,081</td>
<td>76.71</td>
<td>87.22 (81.76 to 100.00)</td>
<td>−4.86 (−2.40 to 3.58)</td>
<td>2.29 (1.52 to 7.63)</td>
</tr>
</tbody>
</table>

INR indicates international normalized ratio; and TTR, therapeutic range.
stroke was greater with very poor control (HR: WCM=2.43
versus TTR=2.10 versus log INR variability=1.74) or poor
control (HR: WCM=1.69 versus TTR=1.46 versus log INR
variability=1.29). Table 4 shows the HRs for stroke according
to quintiles of anticoagulation control.

WCM did not better discriminate patient level outcomes
compared with TTR and INR variability. There was no signifi-
cant improvement in the c-statistics across the 3 models when
examining major bleeding, fatal bleeding, and ischaemic stroke (Table V in the Data Supplement).

Comparing 3 Anticoagulation Measures at Various
Control Levels and as Performance Measures When
Ranking ACC

Patient Population
For these analyses, we included our full sample of 103897
patients who received warfarin anticoagulation from 100 VA
ACCs. Baseline characteristics are described in Table I in
the Data Supplement. The majority of our sample were men
(98%) with an average age of 72 years. The main indication
for warfarin anticoagulation was atrial fibrillation (64%), with
29% for venous thromboembolic disease and 9% for other
indications. Our sample had a substantial burden of physical
illness. For example, 39% had diabetes mellitus and 31%
had heart failure. The median number of patients managed at
each clinic was 862 (interquartile range, 559–1301.8). The mean
and SD for observed minus expected value for all 3 measures
are shown in Table VI in the Data Supplement.

Table 3. Hazard Ratios for Fatal Bleeding Comparing 3
Anticoagulation Measures, TTR, Log INR Variability, and WCM

<table>
<thead>
<tr>
<th>Quintiles</th>
<th>Measurements</th>
<th>TTR</th>
<th>Log INR Variability</th>
<th>WCM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poorest control</td>
<td>2.18 (1.57–2.03)</td>
<td>2.49 (1.79–3.47)</td>
<td>3.04 (2.16–4.28)</td>
<td></td>
</tr>
<tr>
<td>Poor control</td>
<td>1.49 (1.06–2.10)</td>
<td>1.45 (1.02–2.08)</td>
<td>1.67 (1.16–2.42)</td>
<td></td>
</tr>
<tr>
<td>Fair control</td>
<td>1.19 (0.84–1.70)</td>
<td>1.18 (0.81–1.72)</td>
<td>1.45 (0.99–2.11)</td>
<td></td>
</tr>
<tr>
<td>Good control</td>
<td>0.92 (0.68–1.23)</td>
<td>1.18 (0.81–1.71)</td>
<td>1.18 (0.79–1.75)</td>
<td></td>
</tr>
<tr>
<td>Excellent control</td>
<td>Reference</td>
<td>Reference</td>
<td>Reference</td>
<td></td>
</tr>
</tbody>
</table>

Effect across each column was statistically significant at the P<0.001 level.
Effects across rows cannot be directly compared using a statistical test, as the
samples are not independent. INR indicates international normalized ratio; TTR,
therapeutic range; and WCM, warfarin composite measure.

Table 4. Hazard Ratios for Ischemic Stroke Comparing 3
Anticoagulation Measures, TTR, Log INR Variability, and WCM

<table>
<thead>
<tr>
<th>Quintiles</th>
<th>Measurements</th>
<th>TTR</th>
<th>Log INR Variability</th>
<th>WCM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poorest control</td>
<td>2.10 (1.76–2.51)</td>
<td>1.74 (1.46–2.08)</td>
<td>2.43 (2.01–2.92)</td>
<td></td>
</tr>
<tr>
<td>Poor control</td>
<td>1.46 (1.22–1.76)</td>
<td>1.29 (1.07–1.55)</td>
<td>1.69 (1.39–2.05)</td>
<td></td>
</tr>
<tr>
<td>Moderate control</td>
<td>1.08 (0.89–1.31)</td>
<td>1.16 (0.96–1.40)</td>
<td>1.30 (1.06–1.59)</td>
<td></td>
</tr>
<tr>
<td>Good control</td>
<td>0.93 (0.76–1.14)</td>
<td>0.96 (0.79–1.17)</td>
<td>1.18 (0.96–1.46)</td>
<td></td>
</tr>
<tr>
<td>Excellent control</td>
<td>Reference</td>
<td>Reference</td>
<td>Reference</td>
<td></td>
</tr>
</tbody>
</table>

Effect across each column was statistically significant at the P<0.001 level.
Effects across rows cannot be directly compared using a statistical test, as the
samples are not independent. INR indicates international normalized ratio; TTR,
therapeutic range; and WCM, warfarin composite measure.

There was considerable discordance among our mea-
sures in classifying patients’ anticoagulation control. For example, 2.73% patients were classified as having excellent
control according to log INR variability (ie, in the quintile
of excellent control) but poorest control according to TTR
(ie, in the quintile of worse control). Also, 0.71% of patients were
classified to have excellent control according to TTR
but poorest control according to log INR variability. Such
instances of relatively extreme discordance remained but
were less frequent between WCM and its components, where
only 0.05% of patients were classified to have excellent
control according to TTR and poorest control according to
WCM. Similarly, 0.46% of patients were classified to have
the poorest control according to WCM but excellent control
according to log INR variability. No patient classified to have
excellent control according to WCM was classified to have
poorest control according to log INR variability (Tables VII–IX in the Data Supplement).

As would be expected, the risk-adjusted clinic rankings
were strongly correlated between TTR and WCM (r=0.93)
and between log INR variability and WCM (r=0.90), but were
less correlated between TTR and log INR variability (r=0.70).
The correlation also appeared modest when examining the
magnitude of observed minus expected value (rather than
clinic rankings) between TTR and log INR variability (r=0.51,
P<0.001; Figure 1).

A total of 40 ACCs were identified as performance out-
liers by at least 1 of our 3 measures. Profiling ACCs based on
TTR identified 10 high and 10 low performing outliers using
our definition of 1 SD difference from the mean (Figure I in
the Data Supplement); profiling ACCs according to log INR
variability identified 14 high and 12 low performing outli-
ers (Figure II in the Data Supplement); and profiling ACCs
according to WCM identified 13 high and 16 low outliers
(Figure 2). Although there was some overlap regarding which
clinics were identified as performance outliers, it was only
limited overlap. One clinic (Site 74) was actually identified
as a high performing outlier by WCM and a low performing
outlier by TTR. No site was identified as a performing outlier
based on WCM only; all those sites were also a performing
outlier on at least one of the component measures.

Our results indicate that the degree of chance-corrected
agreement in identifying sites that are considered outliers
clinics (both high and low) and nonoutlier clinics, measured
by weighted $\kappa$ score ($\kappa$) between WCM and its components.
is moderate ($\kappa=0.56$ for TTR and $\kappa=0.62$ for log INR variability), whereas the level of agreement between TTR and log INR variability was weak ($\kappa=0.13$).

**Discussion**

We found that a novel composite measure (ie, WCM) produces the largest range of risk for adverse clinical events when benchmarked against excellent anticoagulation control when compared with its components (ie, TTR and log INR variability). This study demonstrates the usefulness of a single composite measure, as opposed to using 2 measures at once. This approach allows providers to address warfarin management in a comprehensive way, addressing the 2 crucial dimensions of anticoagulation control simultaneously. Our results concord with findings of previous studies that demonstrated an advantage in measuring anticoagulation quality using both its important dimensions, intensity and stability.14,15

Measuring anticoagulation using WCM, as a summary score, widens the ceiling and floor measurement effects that limit the use of single measures. We observed that both TTR and INR variability may experience floor or ceiling effects with flat risk associations at either end of the INR control scales. In contrast, WCM does not demonstrate similar floor or ceiling effects, with roughly linear difference in risk across our sample.

The modest agreement between TTR and log INR variability suggests that it is inherently challenging to define what constitutes good or poor anticoagulation control according to a single anticoagulation measure. There are a significant number of patients that could be classified as having poor control according to one measure, whereas having good control according to the other. WCM has the advantage of including both dimensions of what constitutes good anticoagulation control, namely appropriate intensity and stability.
Defining the level of anticoagulation control according to WCM is closely linked to the patient outcomes that inherently matter; it is a truism that intermediate outcome measures should be as tightly linked to definitive outcomes as possible to help ensure that we can work to improve the dimensions that are most related to important clinical outcomes that matter most.\(^5\)

Furthermore, we illustrate the feasibility of profiling ACCs according to 3 different anticoagulation measures (TTR, INR variability, and WCM), and how ACCs performance and ranking would change depending on the measure chosen. Despite the fact that all 3 measures examine anticoagulation control, we illustrate how the choice of one measure can significantly change what might constitute a performance outlier. The concordance between TTR and INR variability in identifying high and low performing clinics was relatively slight. This is not surprising because these 2 measures assess different domains of anticoagulation control. Our results illustrate the general point that ranking sites can markedly change if different measures are adopted. Therefore, the development of a credible composite measure, which combines both TTR and INR variability, is an important step toward reconciling the discordance of using a single measure.

Establishing criterion validity (ie, the ability to predict clinical events) is only part of making a case for a new performance measure. Health systems will also need to convince stakeholders, such as clinical providers, that the new measure is not only valid, but also feasible and easily understood. It is a concern that the new composite measure is even more complex than either of the measures it would replace; however, both the component measures also require a compute to calculate them, so it may be that a certain point of complexity may have been passed already. Nevertheless, it should be recognized that the factual basis for any measure is not sufficient to ensure that it will be embraced by end users.

We acknowledge several limitations in our study. First, our patient-level outcomes were detected using automated data and were not validated by chart review. However, we used thoughtful approaches to using these automated data to maximize the accuracy of our findings. Second, ideally we should have defined levels of anticoagulation control according to clinically meaningful cutoff points. We used quintiles, a generic approach, largely because of a lack of accepted standards regarding what would be a clinically meaningful difference. Third, our sample was overwhelmingly men (98%) and reflects the population of VA patients, limiting to the generalizability of our results to other populations. Fourth, we were not able to generate statistical comparisons across our 3 different measures, because our patients’ groups were not distinctly separated. Fifth, we adjusted for many confounding factors for major bleeding and fatal bleeding; however, we were not able to adjust for all factors, including history of prior bleeding and the use of antiplaletes. In addition our administrative data could not account for other important factors that are related to warfarin complications, including adherence to warfarin therapy. Finally, in addition to our observed minus expected value approach, there are other ways to profile sites based on Bayesian methods, which can be especially important when dealing with small sample size.\(^6\) However, because of our large sample size at even the smallest sites of care, this was not necessary here.

In conclusion, our intermediate composite measure (WCM) summarizes 2 aspects of anticoagulation control, namely intensity and stability. Our findings suggest that WCM has validity in measuring anticoagulation control and is closely linked to adverse events. WCM produced the largest range of risk for ischemic stroke and fatal bleeding compared with its components; this was only true when comparing WCM with log INR variability for major bleeding but not TTR.

We would recommend the use of WCM as a performance measure for clinic profiling, as it seems to identify different clinics as outliers. Both on an empirical and a theoretical basis, WCM captures more completely relevant dimensions of anticoagulation control than its component measures.

Acknowledgments

The opinions expressed are those of the authors and do not necessarily represent the official views or policies of the US Department of Veterans Affairs.

Sources of Funding

Dr Razouki is an awardee of the Office of Academic Affiliations for a Postdoctoral Training Program in Health Services Research, Durham VA Medical Center (TPM 21–026). This study was supported by the Health Service Research & Development IIR-10 to 374 (PI: Dr Rose).

Disclosures

None.

References


Improving Anticoagulation Measurement: Novel Warfarin Composite Measure
Zayd Razouki, James F. Burgess, Jr, Al Ozonoff, Shibei Zhao, Dan Berlowitz and Adam J. Rose

Circ Cardiovasc Qual Outcomes. 2015;8:600-607; originally published online September 29, 2015;
doi: 10.1161/CIRCOUTCOMES.115.001789

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circoutcomes.ahajournals.org/content/8/6/600

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Cardiovascular Quality and Outcomes can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Cardiovascular Quality and Outcomes is online at:
http://circoutcomes.ahajournals.org//subscriptions/